Wave Life Sciences Ltd (NASDAQ:WVE) – Investment analysts at Leerink Swann issued their Q1 2019 earnings estimates for shares of Wave Life Sciences in a report released on Monday. Leerink Swann analyst G. Porges anticipates that the company will earn ($0.62) per share for the quarter. Leerink Swann has a “Outperform” rating and a $62.00 price target on the stock. Leerink Swann also issued estimates for Wave Life Sciences’ Q2 2019 earnings at ($0.65) EPS, Q3 2019 earnings at ($0.68) EPS and Q4 2019 earnings at ($0.72) EPS.
Several other research analysts have also commented on WVE. BidaskClub raised Wave Life Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. TheStreet raised Wave Life Sciences from a “d+” rating to a “c-” rating in a research report on Friday, January 5th. Zacks Investment Research lowered Wave Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, January 13th. Mizuho set a $34.00 target price on Wave Life Sciences and gave the company a “buy” rating in a report on Tuesday, February 20th. Finally, SunTrust Banks boosted their target price on Wave Life Sciences to $60.00 and gave the company a “buy” rating in a report on Friday, March 9th. Two research analysts have rated the stock with a sell rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $47.20.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bridger Management LLC increased its stake in Wave Life Sciences by 16.2% in the fourth quarter. Bridger Management LLC now owns 337,949 shares of the company’s stock valued at $11,862,000 after purchasing an additional 47,064 shares during the last quarter. Perceptive Advisors LLC increased its stake in Wave Life Sciences by 3.1% during the fourth quarter. Perceptive Advisors LLC now owns 662,798 shares of the company’s stock worth $23,264,000 after acquiring an additional 20,000 shares during the last quarter. Two Sigma Investments LP purchased a new stake in shares of Wave Life Sciences in the fourth quarter worth about $828,000. Goldman Sachs Group Inc. purchased a new stake in shares of Wave Life Sciences in the fourth quarter worth about $222,000. Finally, Spark Investment Management LLC purchased a new stake in shares of Wave Life Sciences in the fourth quarter worth about $1,411,000. 79.66% of the stock is owned by institutional investors.
In other Wave Life Sciences news, insider Chris Francis sold 21,639 shares of the business’s stock in a transaction on Tuesday, February 20th. The stock was sold at an average price of $55.40, for a total transaction of $1,198,800.60. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Michael A. Panzara sold 511 shares of the business’s stock in a transaction on Friday, February 16th. The stock was sold at an average price of $52.10, for a total value of $26,623.10. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 24,466 shares of company stock worth $1,321,808. Company insiders own 53.00% of the company’s stock.
About Wave Life Sciences
WAVE Life Sciences Ltd. is a genetic medicines company. The Company, through its synthetic chemistry drug development platform, designs, develops and commercializes a pipeline of nucleic acid therapeutic candidates for genetically defined diseases. The Company is engaged in developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.
Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.